
NYSE:MDT
This summary was created by AI, based on 2 opinions in the last 12 months.
Medtronic Inc (MDT) appears to be in a favorable position in the short to medium term according to expert reviews. The company is seen as benefiting from ongoing market dynamics, particularly as it capitalizes on advancements in AI and a supportive demographic trend involving Baby Boomers. However, concerns regarding its competitive edge have been raised, especially in comparison to peers like Boston Scientific who possess stronger R&D capabilities. Despite these challenges, experts believe that Medtronic's diversification across various medical devices sets it apart from competitors focused solely on specific areas like knee devices. The stock is viewed as a potential trade opportunity rather than a long-term investment, buoyed by successful product launches and an attractive price-to-earnings ratio that could support the stock's performance for the next 12-18 months, but not much beyond that.
Likes this medical device-maker. They presented at today's JPMorgan's healthcare conference. The stocked slipped 1% today after the company trimmed organic growth forecast this quarter because the explosion of Covid cases is forcing the postponement of medical procedures. This happened at a previous conference, so he's not surprised. The Covid issue is temporary and meanwhile more people will get vaccinated that will unleash pent-up demand for MDT's devices.
A large medical tech company, one of the largest in that field. It is a nice industry that he likes. They deliver consistent earnings growth. It is more of an oligopoly market. It could be a core holding in a portfolio to get medical technology exposure. He holds BSX-N, however.